Evidence map›Paper›PMID 37664545›Full record

ArticleFrontiers in pediatrics2023

Genomic signatures and prognosis of advanced stage Chinese pediatric T cell lymphoblastic lymphoma by whole exome sequencing.

Qinglin Liu, Xiang Yu, Jinquan Wen, Nange Yin, Xin Liao, Pinli Zou, Yuxia Guo, Lin Song, Jianwen Xiao

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pediatrics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 72% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Qinglin Liu *First Clinical College of Chongqing Medical University, Chongqing, China.
Xiang Yu *Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, China.
Jinquan WenDepartment of Pediatric Hematology, Hospital of Xianyang Caihong, Shaanxi, China.
Nange YinMinistry of Education Key Laboratory of Child Development and Disorders, Chongqing, China.
Xin LiaoMinistry of Education Key Laboratory of Child Development and Disorders, Chongqing, China.
Pinli ZouMinistry of Education Key Laboratory of Child Development and Disorders, Chongqing, China.
Yuxia GuoMinistry of Education Key Laboratory of Child Development and Disorders, Chongqing, China.
Lin SongMinistry of Education Key Laboratory of Child Development and Disorders, Chongqing, China.
Jianwen XiaoChongqing Key Laboratory of Pediatrics, Chongqing, China.
Chongqing Medical University · CNChildren's Hospital of Chongqing Medical University · CNXian Yang Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To investigate the genomic signatures and prognosis of advanced-stage T cell lymphoblastic lymphoma (T-LBL) and to examine the relationship between T-LBL and T cell acute lymphoblastic leukemia (T-ALL). Methods: 35 Chinese T-LBL children with stage III or IV disease were recruited for this study. They were treated with combination chemotherapy and whole exome sequencing. The relationship of the clinical features, prognosis and specific gene mutations was researched. Gene chips of T-LBL and T-ALL were downloaded from a database, and differential gene expression was analyzed. Results: Germline causal gene mutations (CARS or MAP2K2) were detected in 2 patients; 3.06 ± 2.21 somatic causal gene mutations were identified in the 35 patients, and somatic mutations were observed in the NOTCH1, FBXW7, PHF6 and JAK3 genes. NOTCH1 mutations were significantly associated with FBXW7 mutations, and the age at diagnosis of patients with NOTCH1-FBXW7 mutations was less than that of patients without such mutations ( Conclusion: Although T-ALL and T-LBL both originate from precursor T-cells and are considered different manifestations of the same disease and the outcome of T-LBL is favorable when using T-ALL-based chemotherapy, there are differences in the gene distribution between T-LBL and T-ALL. It seems that the PI3K-Akt signaling pathway and the USP34 gene play important roles in T-LBL, but medicines targeting the USP34 gene or the PI3K-Akt pathway may be invalid.

Indexed as

childrenPI3K-Akt pathwayT cell lymphoblastic lymphomaUSP34 genewhole exome sequencing

Identifiers

PMID37664545
PMCPMC10469305
OpenAlexW4385994312

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.